We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-0.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.89B
AUM Growth
-$643M
Cap. Flow
-$392M
Cap. Flow %
-5.69%
Top 10 Hldgs %
36.47%
Holding
178
New
7
Increased
49
Reduced
68
Closed
19

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$49.8M
2
ALGN icon
Align Technology
ALGN
+$27.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
VEEV icon
Veeva Systems
VEEV
+$13.1M
5
LEGN icon
Legend Biotech
LEGN
+$7.46M

Top Sells

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$159M
2
CI icon
Cigna
CI
+$30.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.6M
4
ELV icon
Elevance Health
ELV
+$26.9M
5
DXCM icon
DexCom
DXCM
+$26.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
2 Industrials 0.84%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
51
Elevance Health
ELV
$80.9B
$42.7M 0.62%
92,970
-56,451
-38% -$26.9M
SILK
52
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$41.9M 0.61%
1,069,739
+57,216
+6% +$2.8M
CRSP icon
53
CRISPR Therapeutics
CRSP
$4.71B
$40.7M 0.59%
899,800
-11,905
-1% -$578K
AMED
54
DELISTED
Amedisys
AMED
$39.9M 0.58%
542,616
-70,896
-12% -$6.13M
MOH icon
55
Molina Healthcare
MOH
$11.7B
$38.1M 0.55%
142,609
-43,405
-23% -$12.5M
GMED icon
56
Globus Medical
GMED
$10.5B
$36.7M 0.53%
647,645
-32,535
-5% -$2.09M
CNC icon
57
Centene
CNC
$32.8B
$34.7M 0.5%
549,341
-144,217
-21% -$10.2M
IQV icon
58
IQVIA
IQV
$34.4B
$34.3M 0.5%
172,478
-10,842
-6% -$2.32M
ZBH icon
59
Zimmer Biomet
ZBH
$17.6B
$34.3M 0.5%
265,270
-1,026
-0.4% -$129K
HUM icon
60
Humana
HUM
$48B
$33.3M 0.48%
68,570
-41,969
-38% -$20.7M
CDNA icon
61
CareDx
CDNA
$2.05B
$31.4M 0.46%
3,439,091
+270,643
+9% +$3.46M
COO icon
62
Cooper Companies
COO
$14B
$30.4M 0.44%
325,252
– –
PFE icon
63
Pfizer
PFE
$143B
$30.2M 0.44%
740,695
-47,978
-6% -$2.07M
HALO icon
64
Halozyme
HALO
$9.23B
$28.4M 0.41%
742,400
-70,300
-9% -$3.3M
PRVA icon
65
Privia Health
PRVA
$3.39B
$27.7M 0.4%
1,002,644
+101,978
+11% +$2.69M
FATE icon
66
Fate Therapeutics
FATE
$324M
$27.7M 0.4%
4,855,779
-5,500
-0.1% -$33.2K
AXSM icon
67
Axsome Therapeutics
AXSM
$11.8B
$27.2M 0.4%
441,350
+4,692
+1% +$308K
OMCL icon
68
Omnicell
OMCL
$2.09B
$27.2M 0.39%
463,367
-55,017
-11% -$3.03M
ATRC icon
69
AtriCure
ATRC
$1.77B
$26.8M 0.39%
647,222
+3,113
+0.5% +$129K
BNTX icon
70
BioNTech
BNTX
$23.1B
$24.5M 0.36%
196,480
-24,600
-11% -$3.38M
LEGN icon
71
Legend Biotech
LEGN
$4.31B
$24.5M 0.35%
507,254
+152,465
+43% +$7.46M
HCM icon
72
HUTCHMED
HCM
$1.86B
$23.8M 0.35%
1,826,970
+46,826
+3% +$767K
EPIX
73
DELISTED
ESSA Pharma
EPIX
$23.5M 0.34%
7,898,583
– –
HOLX
74
DELISTED
Hologic
HOLX
$23.4M 0.34%
290,136
+46,965
+19% +$3.78M
ILMN icon
75
Illumina
ILMN
$28.2B
$23.1M 0.34%
102,036
+4,472
+5% +$915K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2023 Portfolio in Review

As of Q1 2023, Bellevue Group held 178 positions worth $6.89B, down 8.5% from $7.53B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group withdrew a net $392M in Q1 2023, closing 19 positions and reducing 68 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $159M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Verona Pharma worth $5.27M.

  • Bellevue Group's largest Q1 2023 buy was Verona Pharma: 262,683 shares worth $5.27M.
  • Bellevue Group added most to Medtronic in Q1 2023, an estimated $49.8M increase.
  • Bellevue Group's biggest Q1 2023 reduction was Cigna, cutting an estimated $30.6M.
  • Bellevue Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $159M.
  • Bellevue Group's ten largest holdings make up 36% of its $6.89B portfolio in Q1 2023.
  • Bellevue Group opened 7 new positions and closed 19 in Q1 2023.
  • Bellevue Group's portfolio value fell 8.5% quarter-over-quarter to $6.89B.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.